CTHIn ForceLegislation
National Health (Pharmaceutical Benefits) Regulations 2017
73Step 3—average approved ex‑manufacturer price for brand
Start here
Get a plain-English read of 73
Turn the raw legal text into a practical explanation grounded in National Health (Pharmaceutical Benefits) Regulations 2017.
#### 73 Step 3—average approved ex‑manufacturer price for brand
(1) Work out the average approved ex‑manufacturer price of the listed brand of the pharmaceutical item for the data collection period for the brand.
(2) The average approved ex‑manufacturer price is the amount worked out by:
(a) adding together, for each price sampling day for the listed brand for the data collection period:
(i) if the listed brand had an approved ex‑manufacturer price on the price sampling day—the approved ex‑manufacturer price; or
(ii) if the listed brand did not have an approved ex‑manufacturer price on the price sampling day—the approved ex‑manufacturer price of a listed brand of the same pharmaceutical item; and
(b) dividing that amount by the number of price sampling days for the listed brand for the data collection period.
> Note: A price sampling day may be within the data collection period for another brand of the same pharmaceutical item (see section 68).
Adjustment for variation in pricing quantity
(3) If the pricing quantity of a brand on a price sampling day is different from the pricing quantity of the brand on the final day, for the purposes of subsection (2) the approved ex‑manufacturer price of the brand on the price sampling day is taken to be:

where:
> AEMP means the approved ex‑manufacturer price of the brand on the price sampling day (for the pricing quantity of the brand on the price sampling day).
> PQ1 means the pricing quantity of the brand on the price sampling day.
> PQ2 means the pricing quantity of the brand on the final day.